| Field | Specification |
|---|---|
| Mfr No | |
| Clonality | |
| Host | |
| Immunogen | E.coli-derived human IL2 recombinant protein (Position: M1-T153) was used as the immunogen for the IL2 antibody. |
| Isotype | |
| Product Type | |
| Purity | |
| Reactivity | |
| Storage | |
| Target | |
| UniProt # |
Overview
IL2 Antibody / Interleukin 2 is a anti-IL2 Rabbit antibody Polyclonal (rabbit origin) supplied in Lyophilized format. Recommended for workflows such as Western blot (WB), ELISA with listed reactivity in Human, Rat.
Key elements and design rationale
- Target: IL2
- Antibody details: Rabbit, Polyclonal (rabbit origin), isotype Rabbit IgG
- Format: Lyophilized
- Applications (as listed): WB, ELISA
Biological background
IL2 is encoded by the IL2 gene on human chromosome 4q27. The protein is produced primarily by activated CD4+ T cells as a 153-amino acid precursor, which is processed to a 15.5 kilodalton mature secreted cytokine. IL2 binds with high affinity to the heterotrimeric IL2 receptor complex (IL2Ralpha/CD25, IL2Rbeta/CD122, and gammac/CD132), triggering JAK1/3-mediated phosphorylation of STAT5 and subsequent transcription of proliferation and survival genes.
The IL2 antibody detects secreted and intracellular IL2 by western blot or immunoassay, and shows cytoplasmic and perinuclear staining in activated lymphocytes. IL2 drives clonal expansion of T and NK cells, enhances cytotoxicity, and induces differentiation of regulatory T cells to maintain immune balance. Dysregulation of IL2 signaling leads to immune deficiency or autoimmunity, depending on whether its production or receptor function is impaired.
Clinically, IL2 forms the basis for several immunotherapeutic strategies, including recombinant IL2 (aldesleukin) for metastatic melanoma and renal carcinoma. It also serves as a biomarker for T-cell activation in immunomonitoring assays. Genetic polymorphisms in IL2 or its receptor subunits have been associated with autoimmune diseases such as type 1 diabetes, rheumatoid arthritis, and multiple sclerosis.
As a key cytokine in immune communication, IL2 bridges innate and adaptive responses, coordinating activation, tolerance, and memory formation.
Research relevance and current trends
- Connecting protein-level changes to phenotype using orthogonal readouts (genetic perturbation, transcriptomics, imaging).
- Considering isoforms and post-translational regulation when interpreting protein-level changes.
- Comparing results across species and model systems with matched controls.
Common research applications
- Western blotting: compare relative abundance and activation-state changes across conditions.
- ELISA: support antibody-based quantification in assay formats where applicable.
Interpret changes in signal alongside appropriate controls and, when relevant, in parallel with total-protein or pathway readouts.
Notes for experimental interpretation
- Signal can reflect expression level, isoform composition, and post-translational state; interpret results in the context of your model system and stimuli.
- Species differences and sample matrices can influence epitope recognition; prioritize matched controls and orthogonal confirmation when feasible.
Antibody notes: Polyclonal antibodies recognize multiple epitopes, which can broaden the epitope footprint and may increase sensitivity in some contexts.
Customization & Add-ons: Can’t find the antibody you need—or require a custom format for your assay? We can help you source the best match or support custom antibody solutions for diverse research needs, including species and isotype selection, conjugations and labeling (e.g., HRP/AP, biotin, fluorophores), purification grade options (Protein A/G, affinity purified), formulation preferences (buffer selection, carrier-free, glycerol-free), custom concentrations and aliquoting, low-endotoxin options for cell-based work, and application-focused QC/validation support (project dependent). Click Talk to a Scientist to submit a request, email us at support@biohippo.com, or explore our Research Services for additional support—our team will follow up with feasibility details and next steps.
